Biopharma

The blockbuster PARP inhibitor fight intensifies: Focus on ovarian cancer

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry. Poly ADP-ribose polymerase (PARP) inhibitors have created much excitement in the medical community since the demonstration in 2005 of the extreme sensitivity […]

Lung cancer – continued progress in personalized care

This article is a Clarivate Analytics Market Insight report, an ongoing series featuring expert reviews of hot topics in the pharma/biotech field, with analysis and discussion on the factors currently affecting the industry.

Roche’s Ocrevus to dominate the multiple sclerosis market

As it enters the market, Ocrevus (ocrelizumab) is a drug set not only to top the multiple sclerosis (MS) field, but also to be 2017’s biggest future-blockbuster entrant. The 2017 edition of the annual Drugs to Watch report forecasts that seven new drugs including Ocrevus will enter the market in 2017 and achieve blockbuster sales of more than 1 billion by 2021, as evaluated by consensus sales forecast data from Clarivate Analytics Cortellis Competitive Intelligence (source Thomson Reuters I/B/E/S).

Shifts in the FDA’s Approach to Off-Label Promotion

The Regulatory Affairs Professionals Society (RAPS) held its annual conference, the RAPS Regulatory Convergence, from September 17-20 in San Jose, CA. Clarivate Analytics Medical/Regulatory Writer Meg Egan Auderset attended; she wrote the following based on a session called The Changing Landscape of Off-Label Promotion.

Advances in Alzheimer’s, but Knowledge Gaps Remain

The Regulatory Affairs Professionals Society (RAPS) held its annual conference, the RAPS Regulatory Convergence, from September 17-20 in San Jose, CA. Clarivate Analytics Medical/Regulatory Writer Meg Egan Auderset attended; she wrote the following is based on a session about Alzheimer’s disease, Delivering the Next Generation of Alzheimer’s Treatments: Are We Prepared?

Report: Modernizing the Patient Journey with Digital

Report details how to build true-to-life patient journey maps with digital insights

Patient-centricity is the buzzword du jour for pharma marketers, but many fail to factor consumers’ digital behavior into their understanding of the patient journey. Smart brands realize that most of the patient touch points extend beyond the physician consult and that the traditional patient journey is significantly limited in the insights it provides.

For healthcare brands to remain relevant in this marketplace, they must make the patient experience more appealing and meet the heightened expectations of customer service and support across the patient journey. To move away from product-centric marketing messages and design truly patient-centric experiences, brands must understand how patients are leveraging digital channels at each step of their health journey–to gather information, solve problems, make decisions and share their experiences living with a disease. 

 

 

In this report, DRG Digital Principal Analyst Rory Stanton shows brands the impact of digital in patients’ decision making along the health journey, but also how to map patient pain points to customer experience design and marketing strategy.  

 

Key questions addressed in the report: 

How should brands approach mapping the patient journey to drive patient engagement at their organizations? 
How much influence do digital resources have at each stage of the patient journey? 
What are the pain points for patients along the health journey? What role do they expect pharma to play in solving these challenges? 
What digital touch points can brands leverage to improve their patients’ experiences across the health continuum? 
Which brands are investing in patient-centricity and how?

Analysis can be cut by 50+ patient and caregiver audiences

 

 

To buy this report (or learn if your company already owns), please fill out the below form: